# Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct04390295` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04390295](<https://clinicaltrials.gov/study/NCT04390295>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04390295

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

## Technical summary

Registry record NCT04390295. Randomized; quadruple masking; primary purpose treatment. Start 2017-11-02 (actual); primary completion 2020-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT04390295, source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)
- Started: 2017-11-02 (actual) (ClinicalTrials.gov record NCT04390295, source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)
- Primary completion: 2020-05 (anticipated) (ClinicalTrials.gov record NCT04390295, source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)
- Completion: 2020-05 (anticipated) (ClinicalTrials.gov record NCT04390295, source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04390295, source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04390295-2020-05-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Placebo
- Intervention (Drug): SHR3824
- Intervention (Drug): metformin
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: a7ef0eb8de7fbe31b586493d5bd2469071753328e512126ac1bb0479856eefb3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
